Jackson Square Partners LLC Has $20.28 Million Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Jackson Square Partners LLC cut its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 16.7% during the 4th quarter, Holdings Channel reports. The fund owned 61,045 shares of the company’s stock after selling 12,215 shares during the period. Medpace comprises approximately 2.2% of Jackson Square Partners LLC’s investment portfolio, making the stock its 22nd largest position. Jackson Square Partners LLC’s holdings in Medpace were worth $20,281,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also bought and sold shares of MEDP. Pallas Capital Advisors LLC raised its stake in Medpace by 179.7% during the 4th quarter. Pallas Capital Advisors LLC now owns 3,270 shares of the company’s stock worth $1,086,000 after buying an additional 2,101 shares during the period. Barclays PLC increased its stake in Medpace by 71.9% during the 3rd quarter. Barclays PLC now owns 19,781 shares of the company’s stock valued at $6,603,000 after purchasing an additional 8,275 shares in the last quarter. Sanctuary Advisors LLC raised its holdings in Medpace by 20.5% during the fourth quarter. Sanctuary Advisors LLC now owns 4,964 shares of the company’s stock worth $1,738,000 after buying an additional 844 shares during the last quarter. Loomis Sayles & Co. L P lifted its stake in shares of Medpace by 7.2% in the third quarter. Loomis Sayles & Co. L P now owns 205,798 shares of the company’s stock valued at $68,696,000 after buying an additional 13,880 shares in the last quarter. Finally, Cerity Partners LLC increased its position in shares of Medpace by 18.7% during the third quarter. Cerity Partners LLC now owns 61,890 shares of the company’s stock worth $20,659,000 after acquiring an additional 9,741 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts recently issued reports on the company. Robert W. Baird lifted their target price on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a research report on Monday, January 27th. Leerink Partners began coverage on Medpace in a research note on Monday. They issued a “market perform” rating and a $330.00 target price on the stock. Finally, Leerink Partnrs raised Medpace to a “hold” rating in a research report on Monday. Nine research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $376.30.

Medpace Stock Performance

Shares of Medpace stock opened at $330.59 on Tuesday. The stock has a market capitalization of $10.07 billion, a price-to-earnings ratio of 26.17, a price-to-earnings-growth ratio of 3.81 and a beta of 1.47. The company has a fifty day moving average of $337.29 and a 200-day moving average of $339.65. Medpace Holdings, Inc. has a 52-week low of $302.01 and a 52-week high of $459.77.

Medpace (NASDAQ:MEDP) last released its earnings results on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, beating analysts’ consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. On average, equities research analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.